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ABSTRACT
Over the past decade, interest has risen in fermented 
dairy foods that promote health and could prevent dis-
eases such as hypertension. This biological effect has 
mainly been attributed to bioactive peptides encrypted 
within dairy proteins that can be released during fer-
mentation with specific lactic acid bacteria or during 
gastrointestinal digestion. The most studied bioactive 
peptides derived from dairy proteins are antihyper-
tensive peptides; however, a need exists to review the 
different studies dealing with the evaluation of antihy-
pertensive fermented milk before a health claim may be 
associated with the product. Thus, the objective of this 
overview was to present available information related 
to the evaluation of fermented milk containing anti-
hypertensive peptides by in vitro and in vivo studies, 
which are required before a fermented functional dairy 
product may be introduced to the market. Although 
commercial fermented milks with antihypertensive 
effects exist, these are scarce and most are based on 
Lactobacillus helveticus. Thus, a great opportunity is 
available for the development of functional dairy prod-
ucts with new lactic acid bacteria that support heart 
health through blood pressure- and heart rate-lowering 
effects. Hence, the consumer may be willing to pay a 
premium for foods with important functional benefits.
Key words: hypertension, heart rate, antihypertensive 
peptides, in vitro studies, in vivo studies
INTRODUCTION
Interest has been increasing in certain foods, known 
as functional foods that, besides being tradition-
ally nutritional, promote health or reduce diseases 
(Flambard and Johansen, 2007). Among these foods 
are dairy products, as they contain several bioactive 
compounds such as calcium, medium-chain fatty acids, 
CLA, lactose, and peptides (Ebringer et al., 2008). Milk 
proteins are a good source of bioactive peptides, which 
are latent or encrypted within the native protein, and 
some regions of their primary structure contain peptide 
sequences, considered strategic zones, that may exert 
different biological effects (Flambard and Johansen, 
2007). However, because of their latency, they need to 
be released by proteolysis during gastrointestinal diges-
tion or food processing, such as milk fermentation with 
lactic acid bacteria (LAB; Torres-Llanez et al., 2005; 
González-Cordova et al., 2011). Peptide bioavailability 
after oral administration plays a major role because it 
is crucial that they remain bioactive during digestion 
and absorption so that peptides can reach target organs 
and tissues through blood circulation (Vermeirssen et 
al., 2004). Milk bioactive peptides consist of 2 to 20 AA 
residues that, besides being a valuable source of EAA, 
possess specific biological properties (Ricci-Cabello et 
al., 2012); some of these biological properties include 
mineral binding, antioxidant, antithrombotic, antimi-
crobial, opioid, and antihypertensive actions. These re-
leased peptides are present in fermented dairy products 
or are potential ingredients in health-promoting foods 
(Pihlanto et al., 2010; Ricci-Cabello et al., 2012).
Hypertension is a chronic degenerative disease char-
acterized by values of blood pressure exceeding the 
normal range (Chobanian, 2003); it affects more than 
1 billion people worldwide (WHO, 2011). Moreover, it 
is an important risk factor for developing other cardio-
vascular diseases, strokes, renal failure, cerebrovascular 
accidents, and many other complications (Bruce and 
Hanson, 2010). The renin-angiotensin system is the 
most important metabolic pathway in the control of 
blood pressure and vascular tone (Daien et al., 2012). 
The angiotensin-converting enzyme (ACE) plays a 
fundamental role in blood pressure, as it converts an-
giotensin I into angiotensin II, a potent vasoconstrictor; 
it also hydrolyzes the vasodilator peptides bradykinin 
and kallidin. The inhibition of ACE will cause a vaso-
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dilator response, which lowers blood pressure. There-
fore, the pursuit for ACE-inhibitory substances, such 
as peptides, in food has been conducted so that such 
peptides could be used in the prevention and treat-
ment of hypertension (Udenigwe and Mohan, 2014). 
Several ACE-inhibitory peptides have been identified 
in fermented milk and cheese (Pihlanto et al., 2010; 
Hernandez-Ledesma et al., 2011), although their actual 
antihypertensive mechanism is still unclear (Jäkälä and 
Vapaatalo, 2010). Although pharmacological therapies 
are the most widely used to treat hypertension, they 
have long-term secondary side effects. Fermented milk 
is recommended as a nonpharmacological treatment for 
hypertension, mainly because it lacks undesirable side 
effects (Flambard and Johansen, 2007); however, the 
European Food Safety Authority (EFSA) considers 
that the evidence is insufficient.
To date, antihypertensive peptides derived from 
milk proteins are the most studied, and several reviews 
addressing their production, bioavailability, and in-
corporation into foods have been published (Pihlanto 
and Korhonen, 2003; Korhonen and Pihlanto, 2006; 
Hernandez-Ledesma et al., 2011). However, a review 
of in vitro and in vivo studies dealing with the evalu-
ation of antihypertensive peptides in fermented milk 
is needed. Thus, the objective of this overview was to 
present available information related to the evaluation 
of fermented milk containing antihypertensive peptides 
by in vitro and in vivo studies, which are required before 
a fermented functional dairy product can be introduced 
to the market.
IN VITRO STUDIES
The search for ACE-inhibitory peptides by in vitro 
studies is the most common strategy to select ferment-
ed milks with antihypertensive potential. Generally, 
the Cushman and Cheung (1971) spectrophotometric 
method is the most widely used technique for the evalu-
ation of ACE-inhibitory activity. It uses hippuryl-His-
Leu as a substrate, which is hydrolyzed by ACE to 
hippuric acid and His-Leu. However, ACE inhibitors 
ensure this reaction does not take place. This activ-
ity may be expressed as percentage of ACE inhibition 
(ACEI) or as the minimum concentration of protein to 
inhibit 50% of the enzymatic activity (IC50; Hernández-
Ledesma et al., 2011). Once, ACEI is tested and IC50 is 
determined in the water-soluble fraction of fermented 
milk, peptides may be determined by HPLC and mass 
spectrometry.
Most studies have screened different LAB for their 
capacity to exhibit high ACEI activity as a first step 
toward the development of antihypertensive fermented 
milk. Proteolysis by endogenous milk enzymes and en-
zymes from microbial cultures, such as LAB, has been 
shown to produce antihypertensive peptides during 
fermentation. The responsible bacterial enzymes are 
believed to be the cell wall proteinases, which break the 
protein into oligopeptides and use them for nutritional 
sources. The activity of cell wall proteinase, the proteo-
lytic system, and activity of LAB are fundamental for 
the delivery of antihypertensive peptides (Flambard and 
Johansen, 2007). Thus, the specificity of the enzymes 
determines the sequence of the liberated peptides and 
is specific for each strain. Lactic acid bacteria in vitro 
screening for ACEI generally follows 2 approaches: 
the enzymatic characteristics of the bacterial cell wall 
proteinases and the properties of the strains to reduce 
ACE activity in vitro. The first approach was carried 
out in Lactobacillus helveticus, and it was reported that 
3 specific cell wall proteinase patterns were correlated 
with ACEI in vitro (Flambard and Johansen, 2007).
Pihlanto et al. (2010) fermented milk with 25 dif-
ferent LAB and only 5 presented low IC50 in whey 
fractions: Leuconostoc mesenteroides 356 (0.44 mg/
mL), Leuconostoc mesenteroides 358 (0.48 mg/mL), 
Lactococcus lactis ssp. lactis ATCC 19435 (0.5 mg/
mL), Lactobacillus acidophilus ATCC 4356 (0.42 mg/
mL), and Lactobacillus jensenii ATCC 25258 (0.52 mg/
mL). González-Córdova et al. (2011) fermented milk for 
24 h with different Lactobacillus strains; Lactobacillus 
reuteri 14171, Lactobacillus fermentum ATCC 11976, 
and Lactobacillus johnsonii ATCC 33200 exhibited 
42.04 to 83.36% ACEI activity, though Lb. fermentum 
presented the lowest IC50 (21 mg/mL) in whey fraction 
<3 kDa. In a preliminary screening of 20 wild strains of 
Lc. lactis, those isolated from artisanal dairy products 
presented the highest ACEI activity and the lowest IC50 
(13–50 μg/mL) in whey fractions <3 kDa (Rodríguez-
Figueroa et al., 2010). Furthermore, fermented milk 
fractions obtained through reversed-phase HPLC of 2 
Lc. lactis strains showed low IC50 for strains NRRL 
B-50571 (0.034 μg/mL) and NRRL B-50572 (0.041 μg/
mL; Rodríguez-Figueroa et al., 2012).
Another study evaluated ACEI activity in yogurt 
containing additional probiotic strains during refriger-
ated storage (Donkor et al., 2007). Yogurt was prepared 
using either a sole yogurt culture including Lactobacil-
lus delbrueckii ssp. bulgaricus Lb1466 and Streptococcus 
thermophilus St1342, or with Lb. acidophilus L10, Lacto-
bacillus casei L26, or Bifidobacterium lactis B94 besides 
the yogurt culture. All probiotic yogurts showed greater 
ACEI activity during the initial stage of storage (first 
3 wk) versus the control; however, activity decreased 
afterward and IC50 ranged from 27.79 to 103.30 μg/mL 
in whey fractions (Donkor et al., 2007). Thus, studying 
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ACEI stability during product shelf life is important in 
the development of functional fermented milk.
Fermented milks with Lactobacillus strains were the 
most studied for the screening of ACEI activity. Al-
though Pihlanto et al. (2010) reported that fermented 
milk with specific Lactobacillus strains presented IC50 
in the range of 0.42 to 0.52 mg/mL, González-Córdova 
et al. (2011) reported a much higher IC50 range (21–146 
mg/mL) for specific Lactobacillus. On the other hand, 
fermented milk with specific Lactococcus strains pre-
sented the lowest IC50 values (13–50 μg/mL; Rodríguez-
Figueroa et al., 2010). From these reports, it is appar-
ent that ACEI activity and IC50 are strain dependent 
rather than determined by the species.
In vitro studies are the first approach to find po-
tential antihypertensive fermented milks; however, 
their effect in living organisms is required to establish 
a biological effect. The correlations between in vivo 
and in vitro systems are not apparent (Flambard and 
Johansen, 2007). Many of the strains inhibiting ACE 
activity in vitro do not reduce blood pressure in rats. 
The in vitro test mimics only the last interaction of the 
substrate with the ACE, whereas the in vivo system 
involves many other steps comprising many metabolic 
pathways following ingestion and gastrointestinal diges-
tion (Flambard and Johansen, 2007). Hence, in vivo 
studies and clinical trials are necessary to demonstrate 
their physiological effect (Hernandez-Ledesma et al., 
2011).
IN VIVO STUDIES
In vivo studies with spontaneously hypertensive rats 
(SHR) represent a useful animal model to evaluate the 
antihypertensive effect of fermented milk. Hypotensive 
effects have been demonstrated in SHR following oral 
administration of fermented milk (Table 1). Yamamoto 
et al. (1994) fermented milk with 16 different strains 
from 7 species of LAB commonly used in fermented 
dairy products and evaluated their antihypertensive 
effect in SHR. Fermented milk with Lb. helveticus had 
the most hypotensive effect. The systolic blood pres-
sure (SBP) decreased significantly (P < 0.05) after a 
4-h administration of 5 mL/kg of BW of fermented 
milk containing Lb. helveticus CP790 (−27.4 ± 13.3 
mmHg), CP611 (−20 ± 9.6 mmHg), CP615 (−23 ± 
13.4 mmHg), or JCM1004 (−29.3 ± 13.6 mmHg). A 
strong decrease after 8 h of administration was also 
noted, and blood pressure returned to its initial value 
after 24 h.
After the first findings of ACEI milk tripeptides 
Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), several 
investigators have studied their antihypertensive ef-
fects. Nakamura et al. (1995a) were the first to isolate, 
identify, and evaluate these 2 ACEI peptides in in 
vitro and in vivo studies. Furthermore, Nakamura et 
al. (1995b) studied the antihypertensive effect of the 
tripeptides (IPP and VPP) and fermented milk with 
Lb. helveticus and Saccharomyces cerevisiae in SHR. 
Table 1. In vivo studies with spontaneously hypertensive rats (SHR)1
Animal model  Product  Treatment  Results  Reference
SHR Fermented milk After 4 h SBP lowering Yamamoto et al., 1994
SHR Fermented milk After 6 h Dose dependent, lowers BP (P 
< 0.05)
Nakamura et al., 1995b
SHR, normotensive rats Fermented milk mixed 
commercial diet
9 wk SBP lowering, dose dependent Nakamura et al., 1996
SHR, normotensive rats Fermented milk with IPP+VPP After 6 h BP lowering (P < 0.001), ACE 
inhibition, tripeptides detected 
in abdominal aorta
Masuda et al., 1996
SHR α-Lactorphin 13 wk BP lowering Nurminen et al., 2000
SHR Fermented milk with (a) 
IPP+VPP; (b) VPP+IPP
12 wk BP lowering (P < 0.001) Sipola et al., 2001
SHR Fermented milks with IPP+VPP 14 wk BP lowering Sipola et al., 2002
SHR Fermented milk with IPP+VPP, 
IPP+VPP with minerals, 
IPP+VPP
9 wk SBP lowering Jauhiainen et al., 2005a
SHR, normotensive rats Fermented milk 24 h BP lowering Muguerza et al., 2006
 Fermented milk peptides 24 h BP lowering Quiros et al., 2007
SHR Fermented milk with mixed LAB 8 wk BP lowering (P < 0.05) Chen et al., 2007
SHR Fermented milk peptides 8 wk SBP lowering (P < 0.05), nitric 
oxide production
Kim et al., 2010
SHR Fermented milk 24 h Blood pressure and heart rate 
lowering
Rodríguez-Figueroa et 
al., 2012
SHR Fermented milk 4 wk Blood pressure lowering and 
hypolipidemic effect
Rodríguez-Figueroa et 
al., 2013a
1BP = blood pressure; SBP = systolic blood pressure; IPP = isoleucine-proline-proline; VPP = valine-proline-proline; LAB = lactic acid bacte-
ria; ACE = angiotensin-converting enzyme.
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After a single oral administration of fermented milk 
(5 mL/kg of BW), SBP decreased significantly after 6 
to 8 h. The SBP of SHR that ingested the tripeptides 
also decreased after several hours. Moreover, all groups 
(IPP, VPP, and fermented milk) were significantly 
different from the control. Additionally, Nakamura et 
al. (1995b) administered fermented milk (25 mL/kg of 
BW) or tripeptides (10 mg/kg of BW) and SBP did not 
change in normotensive rats. They concluded that the 
hypotensive effect of tripeptides and fermented milk 
was specific to the hypertensive state (Nakamura et al., 
1995b).
Another study by Nakamura et al. (1996) mixed ly-
ophilized fermented milk (0.25, 1.25, and 2.50% wt/
wt) containing Lb. helveticus and Sac. cerevisiae with 
a standard commercial diet. The test group of SHR 
was fed with this mixed diet and for the control group 
they were fed with a standard commercial diet. The 
SBP of the control group increased during the course 
of the experiment to reach about 220 mmHg at 17 wk. 
However, the SBP of the SHR test group tended to be 
lower—in a dose-dependent manner—than that of the 
control group when they were 13 wk old. Nakamura 
et al. (1996) concluded that the fermented milk not 
only had an antihypertensive effect after a single oral 
administration, but also had hypotensive effect follow-
ing long-term feeding. Moreover, they analyzed ACE 
activity in different organs. They found a significant 
difference in ACE activity between aortas of the test 
group versus those of the control group and concluded 
that ACEI may be a possible mechanism of action (Na-
kamura et al. 1996).
Masuda et al. (1996) evaluated blood pressure, ACE 
activity, and the absorption of IPP and VPP in SHR 
and normotensive rats after 6 h of oral administration 
of 10 mL/kg of BW fermented milk with Lb. helveticus 
and Sac. cerevisiae containing these peptides or saline 
as control. In SHR on the fermented milk group, SBP 
decreased significantly (26.4 ± 3.1 mmHg; P < 0.05), 
and it did not change in normotensive rats that were 
administered with fermented milk. The ACE activity 
was measured in abdominal aorta, lung, kidney, heart, 
and brain in SHR given fermented milk and was signifi-
cantly lower (P < 0.05) than in the control group. Both 
IPP and VPP were detected in the abdominal aorta in 
SHR on the fermented milk group and not detected in 
the saline group; neither was detected in normotensive 
rats given fermented milk or saline. They concluded 
that these tripeptides were absorbed directly without 
being hydrolyzed by digestive enzymes, reached the ab-
dominal aorta, inhibited ACE, and showed hypotensive 
effects in SHR (Masuda et al., 1996).
A study by Nurminen et al. (2000) investigated the 
antihypertensive effect of α-lactorphin (a tetrapeptide: 
Tyr-Gly-Leu-Phe) in SHR and normotensive rats. This 
peptide reduced blood pressure dose-dependently with-
out affecting heart rate in normotensive and SHR. The 
greatest blood pressure reduction was with 100 μg/kg 
of BW in SHR, where SBP was reduced by 23.4 mmHg 
and DBP was reduced by 17.4 mmHg. Although the 
involvement of the endogenous opioid system in car-
diovascular regulation is not well understood, those au-
thors concluded that this peptide possessed opioid-like 
activity in addition to helping modulate blood pressure 
(Nurminen et al., 2000).
Sipola et al. (2001, 2002) performed 2 long-term 
studies with SHR. In the first study, they evaluated 
the effect of treatments during the development of 
hypertension. They administered fermented milk with 
Lb. helveticus LBK16H enriched with VPP and IPP 
(fermented milk group), VPP and IPP dissolved in 
water (peptide group), and water (control group) to 
6-wk-old young prehypertensive SHR. Blood pressure 
increased gradually every week; at wk 10, it persisted 
in a stable hypertensive level in all groups. The fer-
mented milk and peptide groups attenuated the de-
velopment of hypertension in SHR compared with the 
control group (P < 0.01). By wk 12 in the treatment 
period, SBP was 12 mmHg lower than in the control 
group. Moreover, the fermented milk group had a SBP 
17 mmHg lower than the control group. After a follow-
up treatment, SBP from these 2 groups reached the 
same level as the control group. Sipola et al. (2001) 
concluded that long-term intake of fermented milk 
with tripeptides or IPP + VPP may help attenuate 
hypertension in SHR, and could be used as a nonphar-
macological treatment for humans. In a second study, 
Sipola et al. (2002) evaluated the long-term effect of 
fermented milk products on the development of hyper-
tension. They administered fermented milk with Lb. 
helveticus LBK16H with tripeptides IPP + VPP (FM 
A), and the previously reported fermented milk with 
Lb. helveticus and Sac. cerevisiae (FM B; Nakamura 
et al., 1995a). Again, they observed that hyperten-
sion was significantly attenuated (P < 0.05) in the 
fermented milk groups FM A and FM B rather than 
in the control group (water) and skim milk group. By 
wk 14, SBP from the FM A was 10 mmHg lower than 
the FM B and 21 mmHg lower than the control group. 
This could be explained because the FM A had larger 
intake of tripeptides than the FM B group. They con-
cluded that fermented milk with tripeptides helped to 
attenuate hypertension in SHR (Sipola et al., 2002). 
Moreover, these results confirm what was previously 
reported (Sipola et al., 2001) and reinforced that 
fermented milks containing these tripeptides (IPP + 
VPP) may be used for nonpharmacological prevention 
of hypertension.
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Jauhiainen et al. (2005a) evaluated the development 
of hypertension and the effects on arterial function 
in SHR. They administered different treatments to 
each group: (a) tap water, (b) minerals (potassium, 
calcium, magnesium, and sodium), (c) IPP + VPP 
and minerals, or (d) fermented milk Lb. helveticus, 
IPP + VPP, and minerals. After the intervention, the 
group provided with fermented milk with tripeptides 
and minerals attenuated hypertension more effectively 
than pure tripeptides or tripeptides with minerals. 
The water group had the highest SBP. Compared with 
the water group, the tripeptides and minerals group 
and the fermented milk with tripeptides and minerals 
groups presented a reduction in SBP of 12.7 and 16.9 
mmHg, respectively. Though the tripeptide and miner-
als group were also associated with the improvement of 
endothelium-dependent relaxation, the fermented milk 
group demonstrated a greater antihypertensive effect 
(Jauhiainen et al., 2005a). Though no significant dif-
ferences were noted between groups (P > 0.05), those 
authors concluded that this fermented milk could be 
used as a functional food.
Muguerza et al. (2006) isolated different LAB from 
raw cow milk and evaluated the ACEI activity of fer-
mented milk with these LAB. Later, they fermented 
milk with 4 selected strains with different strains of 
Enterococcus faecalis (which had the most ACEI ac-
tivity), obtained the whey fraction, and evaluated the 
antihypertensive effect in SHR and normotensive rats 
after a single oral administration. Those SHR treated 
with water and unfermented milk (controls) had similar 
blood pressure values (SBP and diastolic blood pres-
sure, DBP) throughout the whole experiment. Systolic 
blood pressure and DBP from SHR treated with Cap-
topril (50 mg/kg of BW; Sigma-Aldrich, St. Louis, MO) 
had their maximal decrease 6 h after administration. 
As for the fermented milks, their maximal decreases 
were observed 4 h after administration. Diastolic blood 
pressure were similar to those of the Captopril group; 
however, SBP reduction was less pronounced compared 
with Captopril. Furthermore, no differences (P > 0.05) 
were noted in blood pressure of normotensive rats 
treated with any of the interventions, which suggests 
that the effect of fermented milk with these LAB is 
specific to the hypertensive state. Those authors con-
cluded that raw bovine milk is a good source of LAB, 
which can be used as starter cultures with potential 
applications for the dairy industry in the generation 
of novel products with an added health value, such as 
antihypertensive activity (Muguerza et al., 2006).
Quiros et al. (2007) isolated and identified the pep-
tides responsible for the effect of fermented milk with 
different strains of Enterococcus faecalis reported by 
Muguerza et al. (2006). They conducted in vitro and 
in vivo studies with SHR administered with peptides 
identified in fermented milk. Water was used as a 
negative control because blood pressure did not change 
throughout the experiment. Captopril (50 mg/kg) was 
used as the positive control, as it decreased blood pres-
sure after 4 to 6 h after administration. After a 4-h 
administration of peptide β-CN f(133–138) LHLPLP 
(2 mg/kg), blood pressure also decreased significantly 
(P < 0.05), though it was less pronounced than with 
Captopril. Nevertheless, after a 2-h administration of 
this peptide, DBP in SHR decreased even more than 
Captopril group. Furthermore, 6 mg/kg of the peptide 
β-CN f(58–76) LVYPFPGPIPNSLPQNIPP caused 
a significant (P < 0.05) maximum decrease on blood 
pressure at 6 h after administration. They concluded 
that the administration of LHLPLP at 2, 4, and 6 h 
post-administration decreased SBP and DBP even 
more than IPP and VPP, as previously reported (Na-
kamura et al., 1995a,b).
A study by Chen et al. (2007) evaluated whether the 
combination of milk fermentation by LAB (Lb. casei, 
Lb. acidophilus, Strep. thermophilus, Lb. bulgaricus, 
and Bifidobacterium) and proteolysis with Prozyme 6 
(Amano Pharmaceutical Co., Nagoya, Japan) might 
accelerate the production of antihypertensive peptides 
from traditional dairy products. Chen et al. (2007) 
evaluated the antihypertensive effect of fermented 
milk whey fraction on SHR during the development 
of hypertension. In the first 2 wk, no significant dif-
ferences (P > 0.05) were observed among the SHR in 
fermented milk and the control. However, by the fourth 
week, SBP of the SHR in the fermented milk group was 
significantly (P < 0.05) lower than that of the control 
group. By wk 8, the SBP and DBP were 22 and 21.5 
mmHg lower (P < 0.05) than those from the control 
group, respectively. This effect was mainly attributed 
to tripeptides Gly-Thr-Trp and Gly-Val-Trp. Hence, 
this fermented milk whey may be used as a functional 
ingredient for the prevention of hypertension.
Kim et al. (2010) evaluated aortic thickness and 
whether the administration of fermented milk produced 
with Lb. helveticus and Sac. cerevisiae to SHR lowered 
blood pressure by modulating ACE activity or produc-
ing NO. For the control groups, one group was admin-
istered skim milk and the other group was administered 
Captopril. Whereas the SBP of the Captopril group 
was modulated throughout the intervention, the fer-
mented milk group had significantly (P < 0.05) sup-
pressed SBP compared with the skim milk group. The 
Captopril and fermented milk groups showed ACEI 
activity in serum and abdominal aorta tissue extract, 
which was significantly higher than that in the skim 
milk group (P < 0.05). Moreover, plasma NO concen-
tration was significantly higher in the fermented milk 
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and Captopril groups than in the skim milk group (P 
< 0.05). Similarly, the mean aortic thickness was sig-
nificantly less in the fermented milk and the Captopril 
groups than in the skim milk group (P < 0.05). Thus, 
Kim et al. (2010) concluded that peptides in fermented 
milk not only inhibit ACE activity, but also produce 
the vasodilator NO, which attenuates hypertension in 
SHR (Kim et al., 2010). It is known that NO produced 
and released in the endothelium is considered a main 
vasodilator; thus, the impairment of its production in 
SHR precedes the development of hypertension (Cru-
zado et al., 2002).
Rodríguez-Figueroa et al. (2013b) administered a 
single dose (35 or 50 mg/kg of BW) of fermented milk 
with Lc. lactis strains NRRLB-50571 or NRRLB-50572 
to SHR. Blood pressure was measured at 2, 4, 6, and 
24 h after administration. Maximal reductions of SBP 
and DBP were observed at 6 h after administration 
from Captopril (40 mg/kg of BW). However, fer-
mented milk with NRRL-B50571 (35 mg/kg of BW) 
or NRRL-B50572 (50 mg/kg of BW) also had maximal 
reductions at 6 h after administration. Furthermore, 
24 h after single oral administration, SBP in SHR on 
fermented milk with NRRL-B50572 (50 mg/kg of BW) 
was not significantly different from those on Captopril 
(P > 0.05). Because heart rate reduction may be an 
important strategy for the treatment of a wide range of 
cardiac disorders, those authors evaluated not only the 
antihypertensive effect of these fermented milks, but 
also the heart rate-lowering effect. Heart rate was also 
decreased after 24 h of fermented milk administration.
Another study by Rodríguez-Figueroa et al. (2013a) 
evaluated the antihypertensive and hypolipidemic ef-
fect in SHR of fermented milk with Lc. lactis (NRRL-
B50571 or NRRL-B50572) administered ad libitum 
after a long-term administration (4 wk). Fermented 
milk reduced blood pressure and its maximal effect was 
recorded by the second and third week with NRRL-
B50571 fermented milk, which was not significantly 
different from Captopril (P > 0.05). Furthermore, fer-
mented milk also had a hypolipidemic effect. However, 
clinical studies are necessary to evaluate their effect in 
humans.
Initially, most in vivo studies with SHR were per-
formed with milk fermented with Lb. helveticus in a 
single dose (Yamamoto et al., 1994; Nakamura et al., 
1995b, 1996; Masuda et al., 1996) and after long-term 
administration (Sipola et al., 2001, 2002; Jauhiainen et 
al., 2005a). Those authors attributed the antihyperten-
sive effect to the ACEI tripeptides IPP and VPP. How-
ever, other possible mechanisms for these tripeptides 
beyond ACEI may exist (Jäkälä et al., 2010; Kim et al., 
2010). Other in vivo studies with SHR were carried out 
by administering fermented milk with wild strains of E. 
faecalis in a single dose (Muguerza et al., 2006). In re-
cent years, authors explored the antihypertensive effect 
on SHR of fermented milk with wild strains of Lc. lactis 
in a single dose (Rodríguez-Figueroa et al., 2013b) and 
after long-term administration (Rodríguez-Figueroa 
et al., 2013a). These fermented milks contained ACEI 
peptides other than IPP and VPP (Quiros et al., 2007; 
Rodríguez-Figueroa et al., 2012).
Although most authors attribute the hypotensive ef-
fect of fermented milk to ACEI peptides, other possible 
antihypertensive mechanisms may be involved (Kim et 
al., 2010; Marques et al., 2012; Udenigwe and Mohan, 
2014; Majumder and Wu, 2015). Hence, it is necessary 
to carry out in vivo studies with SHR for evaluating 
these other possible mechanisms. Detailed knowledge 
of peptide structural requirements for antihypertensive 
activity and the mechanisms involved beyond ACEI 
will allow for the design of functional fermented milk 
with a blood pressure-lowering effect.
CLINICAL STUDIES
Several studies have been performed in humans 
(Table 2), where the principal objective is to ensure a 
hypotensive effect of these fermented milks. These are 
randomized controlled clinical trials, which have a test 
group versus a control (placebo) group. Milk fermented 
by Lb. helveticus and Sac. cerevisiae is the most widely 
studied for its antihypertensive effect (Hata et al., 1996; 
Kajimoto et al., 2002; Hirata et al., 2002; Seppo et al., 
2002, 2003; Nakamura et al., 2004; Mizushima et al., 
2004; Jauhiainen et al., 2005b).
Hata et al. (1996) provided 95 mL/d of fermented 
milk with Lb. helveticus and Sac. cerevisiae with tripep-
tides (1.1 mg of IPP + 1.5 mg of VPP) to the test group 
and 95 mL/d of acidified milk to the control group in 
a study of 30 hypertensive subjects treated with hypo-
tensive medication. In the test group, a significant (P 
< 0.05) decrease was noted in wk 4 (9.4 ± 3.6 mmHg) 
and 8 (14.1 ± 3.1 mmHg) for SBP; however, for DBP, 
a decrease of 6.9 ± 2.2 mmHg was observed until wk 8 
of ingestion. In the placebo group, SBP and DBP did 
not decrease significantly (P > 0.05) during treatment. 
Although subjects were treated with antihypertensive 
medication, a greater decrease of blood pressure was 
noted in the test group versus the control group. The 
authors concluded that daily consumption of the prod-
uct for at least 8 wk was required for a reduction in 
blood pressure (Hata et al., 1996). Their study had 
several limitations. First, the groups’ clinical character-
istics (weight and body mass index) were significantly 
different, resulting in heterogeneous groups. This was a 
problem because random assignment should ensure ho-
mogeneous or comparable groups. Randomization dis-
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Table 2. Clinical trials with antihypertensive fermented milks
Subject  
(n)  Hypertension  
Test product: 
Fermented milk  Dose test product  Control product  
Treatment  
(wk)  
Results: Δ test  
group vs. control group1  Reference
30 Hypertension stage 1; 
hypotensive medication
Lactobacillus helveticus 
and Saccharomyces 
cerevisiae
95 mL/d (1.1 mg of 
IPP + 1.5 mg of VPP)
Acidified milk 8 −9.7 ± 3.35 mmHg SBP** Hata et al., 
1996−4.4 ± 2.2 mmHg DBP*
64 Hypertension stage 1; no 
hypotensive medication
Lb. helveticus and 
Sac. cerevisiae; Lb. 
helveticus CM4
150 mL, twice per day 
(1.12 mg of IPP + 
0.79 mg of VPP)
Fermented milk 
with Lb. bulgaricus 
and Streptococcus 
thermophilus
8 −13 ± 10.55 mmHg SBP** Kajimoto et 
al., 2002−8.4 ± 7.45 mmHg DBP**
32 Hypertension stage 1 
and 2; no hypotensive 
medication
Lb. helveticus and 
Sac. cerevisiae; Lb. 
helveticus CM4
120 mL/d (1.6 mg of 
IPP + 2.66 mg VPP)
Acidified milk 8 −12.1 ± 10.2 mmHg SBP* Hirata et al., 
2002−5.8 ± 9.6 mmHg DBP*
39 Hypertension stage 1; 
hypotensive medication
Lb. helveticus 150 mL/d (2.25 mg of 
IPP + 3 mg of VPP)
Fermented milk 
with Lactococcus 
spp.
21 −6.7 ± 2.55 mmHg SBP* Seppo et al., 
2003−3.6 ± 1.45 mmHg DBP
106 Prehypertension; no 
hypotensive medication
Lb. helveticus and 
Sac. cerevisiae; Lb. 
helveticus CM4
2 × 150 mL/d (1.13 
mg of IPP + 0.74 mg 
of VPP)
Skim milk 12 −6.1 ± 7.05 mmHg SBP** Nakamura et 
al., 2004−3.8 ± 6.75 mmHg DBP**
46 Prehypertension no 
hypotensive medication
Lb. helveticus and Sac. 
cerevisiae
160 g/d (1.2 mg of 
IPP + 2.0 mg of VPP)
Acidified milk 4 −1.5 ± 8.55 mmHg SBP* Mizushima et 
al., 2004−1.7 ± 8.85 mmHg DBP
94 Hypertension stage 1; no 
hypotensive medication
Lb. helveticus 2 × 150 mL/d (11.25 
mg of IPP + 15 mg of 
VPP)
Fermented milk 
with Lactococcus 
spp.
10 −4.1 ± 6.6 mmHg SBP Jauhiainen et 
al., 2005b−1.8 ± 3.7 mmHg DBP  
1SBP = systolic blood pressure; DBP = diastolic blood pressure.
*P < 0.05; **P < 0.01.
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tributes individual differences equally across the groups 
so that the groups systematically differ only in the way 
that they have been treated (Armijo-Olivo et al., 2009). 
Another limitation was that subjects who did not show 
good adherence were excluded from the analysis, in-
stead of doing intention-to-treat analysis (ITT). An 
ITT analysis includes every subject who is randomized 
according to randomized treatment assignment. It ig-
nores noncompliance, protocol deviations, withdrawal, 
and anything that happens after randomization. The 
ITT analysis is described as once randomized, always 
analyzed (Gupta, 2011).
In another randomized, double blinded, placebo-con-
trolled study with hypertensive subjects (without hy-
potensive medication; Kajimoto et al., 2002), test and 
control groups ingested 150 mL of the product twice a 
day (morning and evening). Subjects were administered 
fermented milk with Lb. helveticus and Sac. cerevisiae 
and fermented milk by Lb. helveticus CM4 mixture 
with (1.12 mg of VPP + 0.79 mg of IPP) as the test 
group. The control group ingested milk fermented with 
Lb. bulgaricus and Strep. thermophilus as placebo. In 
the test group, SBP and DBP decreased significantly 
(P < 0.01) by the first week compared with control 
group. By wk 8, SBP decreased by 13.9 ± 11.4 mmHg 
and DBP decreased by 9.1 ± 7.5 mmHg compared with 
the control group. Moreover, after the treatment ended, 
blood pressure from the test group returned to its initial 
value (Kajimoto et al., 2002). In their study, it was not 
reported if groups resulting from randomization were 
homogeneous and statistically equal. Also, the placebo 
drink was fermented milk, which could have itself pro-
vided antihypertensive bioactive peptides.
Hirata et al. (2002) performed an 8-wk double blind 
controlled trial with untreated subjects with mild or 
moderate hypertension (140–180 mmHg SBP and 90–
105 mmHg DBP). The test product was prepared with 
a mixture of fermented milk with Lb. helveticus and Sac. 
cerevisiae, and Lb. helveticus CM4 with 1.6 mg of IPP 
+ 2.66 mg of VPP. The control product was artificially 
acidified milk as placebo. Both groups ingested 120 mL 
of the product. After the 8-wk intervention, SBP of the 
test group decreased by 14.5 ± 9.9 compared with the 
baseline, with a significant (P < 0.05) difference of 12.1 
± 10.2 between the test group and the control group. 
In DBP, a significant decrease of 8.1 ± 10 mmHg from 
the baseline was noted in the test group, though no 
significant difference was observed in the control group. 
Given the effectiveness of the fermented milk product, 
Hirata et al. (2002) concluded that it could be used for 
hypertension management. However, they did not men-
tion whether group allocation was carried out through 
randomization. Additionally, it was not reported if ITT 
analysis was used.
Seppo et al. (2002) administered 150 mL of ferment-
ed milk with Lb. helveticus LBK16H with tripeptides 
(IPP and VPP) once a day to the study group. In this 
short-term study (8 wk), SBP and DBP decreased 
significantly (P < 0.05) compared with the control 
group. Although blood pressure was lower in the test 
group than in the control group, this study could not 
be considered as a preliminary one because the number 
of participants was relatively small (17 volunteers). 
Later, Seppo et al. (2003) carried out a long-term study 
(21 wk) with hypertensive subjects who were taking 
hypotensive medication. The test group was adminis-
tered with fermented milk with Lb. helveticus LBK16H 
with tripeptides (IPP and VPP) and the control group 
with fermented milk with Lactococcus spp. The SBP 
decreased significantly (P < 0.05) in comparison to the 
control group (6.7 ± 3 mmHg), although there was no 
significant difference between groups in DBP (P > 0.05; 
Seppo et al., 2003). That study also used fermented 
milk with Lactococcus spp. as the placebo, which could 
have led to the production of bioactive antihypertensive 
peptides. Hence, this could explain why their study did 
not report significant differences between the treatment 
and placebo groups. Furthermore, it was not specified 
which pharmacological antihypertensive medications 
were used by the subjects. Also, in this study ITT 
analysis was not reported.
In a placebo-controlled, double blind study of 12-
wk intervention, Nakamura et al. (2004) administered 
150 mL twice a day of a mixture of fermented milk 
with Lb. helveticus and Sac. cerevisiae + Lb. helveticus 
CM4-fermented milk + fermented milk with Lb. del-
brueckii ssp. bulgaricus and Strep. thermophilus to the 
test group. The control group received skim milk as 
placebo. By the wk 12 intervention, SBP from the test 
group decreased significantly by 6.1 ± 5.7 mmHg (P < 
0.05) from its initial value and was significant different 
from the control group (P < 0.05). Moreover, the test 
group DBP was reduced by 3.8 ± 6.3 mmHg by wk 
12 (P < 0.05). Although a small reduction in blood 
pressure was noted, the sample size was big enough to 
give enough statistical power to detect significant dif-
ferences between groups (Nakamura et al., 2004).
Mizushima et al. (2004) performed a 4-wk clinical 
trial with hypertensive men (≥130/85 mmHg blood 
pressure) with no history of antihypertensive drugs. The 
supplementary drink for the test group was prepared as 
previously reported by Nakamura et al. (2004), where 
skim milk was fermented with Lb. helveticus and Sac. 
cerevisiae. The control drink was artificially acidified 
skim milk as a placebo. Both study groups ingested 
160 mL of their respective product. By wk 2, SBP in 
the test group decreased by 4.3 ± 8.5 and DBP by 
1.7 ± 9.9 mmHg; by wk 4, SBP decreased by 5.2 ± 
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8.1 mmHg and DBP decreased by 2.0 ± 8.6 mmHg, 
values that were significantly (P < 0.05) different from 
the baseline. Although the test group had a greater 
decrease in blood pressure than the placebo group, it 
was not significantly (P > 0.05) different. This might 
be because the sample size was not large enough to 
give enough statistical power to detect the difference 
(Mizushima et al., 2004). In their study, ITT analysis 
was not reported.
A randomized, double blind, controlled clinical study 
of 10 wk was performed by Jauhiainen et al. (2005b). 
The test group was administered twice a day with 150 
mL of fermented milk with Lb. helveticus LBK16H 
with tripeptides (IPP + VPP). The control group 
received 150 mL of fermented milk with Lactococcus 
spp. twice a day. This study differed from other clini-
cal trials because they used a 24-h ambulatory blood 
pressure measurement, which is a reliable method that 
avoids the “white coat hypertension” effect. The SBP 
of the test group decreased by 4.7 ± 10 mmHg and 
DBP decreased by 2.7 ± 8 mmHg by wk 10. Systolic 
blood pressure was significantly (P < 0.05) different 
from that at baseline, but it was not different from the 
control group (P > 0.05). In their study, the control 
group, which was fermented milk, could have provided 
antihypertensive peptides.
Most clinical trials were carried out with Lb. helveticus 
and Sac. cerevisiae fermented milk with tripeptides IPP 
and VPP. However, most recently the antihypertensive 
effect of fermented milk with Lc. lactis NRRLB-50571 
was evaluated in hypertensive subjects in a randomized 
controlled clinical study (Beltran-Barrientos, 2013). 
Fermented milk was prepared as previously reported by 
Rodríguez-Figueroa et al. (2010, 2012, 2013a). The test 
group received 150 mL of fermented milk and the con-
trol group received 150 mL of acidified milk as placebo. 
By the end of the 8-wk intervention, SBP decreased by 
13 ± 12.4 mmHg and was significantly (P < 0.05) dif-
ferent from control group. Although a small reduction 
in DBP was noted, the sample size was not large enough 
to give sufficient statistical power to detect significant 
differences between groups (Beltran-Barrientos, 2013).
Although the antihypertensive effect of the tripep-
tides IPP and VPP has been reported in multiple clini-
cal trials, the EFSA (2011) published an opinion of the 
Panel on Dietetic Products, Nutrition, and Allergies in 
the scientific substantiation of a health claim related 
to IPP and VPP and the maintenance of normal blood 
pressure. The EFSA (2011) identified 20 published 
intervention studies, some of which were adequately 
powered to detect small differences between groups in 
SBP, though there were no differences in DBP. Other 
studies displayed major methodological limitations, 
such as randomization, treatment allocation, blinding, 
and statistical analysis. The panel concluded that a 
cause and effect on the consumption of IPP and VPP 
and the maintenance of normal blood pressure has not 
been established (EFSA 2011). Furthermore, in a meta-
analysis of 19 human clinical trials, the efficacy of the 
tripeptides IPP and VPP for lowering blood pressure 
in prehypertensive or mildly hypertensive subjects was 
demonstrated; however, antihypertensive effects were 
not observed in all individual studies (Turpeinen et al., 
2013).
According to Jäkälä and Vapaatalo (2010), the prob-
lem in the functional food research is that differences 
in human studies are usually quite small between the 
active and placebo treatment, so the study population 
needs to be very large to prove the efficacy conclusively. 
Jäkälä and Vapaatalo (2010) suggested that more em-
phasis should be given to preclinical studies, providing 
that results are consistent and effects are shown repeat-
edly and by several research groups. Also, with sound 
hypotheses and well-defined methods, these studies can 
give valuable information. Thus, it appears that, for the 
time being, antihypertensive lactotripeptide-containing 
milk products do not have approved health claims in 
the European Union (Jäkälä and Vapaatalo, 2010).
In some countries, government regulations have set 
requirements for health claims on functional foods, 
which includes, among other requirements, evidence of 
physiological effects in human subjects. Consequently, 
verifying health claims and commercialization of func-
tional products require substantial research investment. 
Furthermore, obtaining health claims in countries 
where regulations exist remains a challenging process 
that may hinder commercialization of functional food 
products (Udenigwe, 2014).
ANTIHYPERTENSIVE FERMENTED MILK  
AS A FUNCTIONAL FOOD
As hypertension continues to increase worldwide, 
the search for and production of antihypertensive 
functional foods has increased. Several fermented milk 
products are on the market, including Ameal (Calpis 
Co., Tokyo, Japan), Calpis (Calpis Co.), and Evolus 
(Valio, Helsinki, Finland), among others (Table 3). Al-
though these products attribute their antihypertensive 
effect to the bioactive peptides present in the fermented 
milk, they also contain minerals such as potassium and 
calcium, which have been demonstrated to have a posi-
tive effect on blood pressure (Phelan and Kerins, 2011; 
Ricci-Cabello et al., 2012).
Scientifically proven health claims and acquisition 
of exclusivity rights of using novel food ingredients in 
functional food products has been observed as a critical 
factor in the ultimate success of these food products in 
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the market (Khan et al., 2013). Indeed, several of these 
commercial products carry intellectual property rights. 
The technology surrounding Lb. helveticus Cardi-04 
(Chr. Hansen, Hørsholm, Denmark) is protected by 
several patent applications. These include the use of 
LAB to prepare antihypertensive peptides and func-
tional foods containing these [WO 2003/082019 A3 
(Flambard, 2003) and WO 2004/015125 A1 (Flambard, 
2004a)], as well as fermented food products containing 
bioactive compounds that reduce the heart rate (WO 
2004/089097 A1; Flambard, 2004b; Flambard and Jo-
hansen, 2007). Recently, the technology using Lc. lactis 
(NRRL-B50571) for the production of fermented milk 
with antihypertensive peptides was protected by a US 
patent (US 8,865,155; Vallejo Galland et al., 2014).
CONCLUSIONS AND FUTURE TRENDS
Hypertension is a disease that affects not only adults, 
but also children worldwide. Although antihypertensive 
drugs play a fundamental role in blood pressure regula-
tion, they can present several side effects; therefore, a 
number of studies have searched for food substances 
that can help reduce or prevent hypertension. Some 
fermented milks have been demonstrated in vitro, in 
vivo, and in clinical trials to be antihypertensive agents, 
and their effects in most cases have been attributed to 
milk peptides. These fermented milks are as effective 
as synthetic ACEI; therefore, they can be considered 
as hypotensive agents because they can form part of 
the daily diet. Although a great deal of research related 
to antihypertensive peptides has been done, there is a 
need to find and evaluate new LAB that possess the 
ability to generate this bioactivity as well as good tech-
nological properties for the production of fermented 
dairy products. As commercial fermented milks with 
antihypertensive effects are scarce and most are based 
on Lb. helveticus, a great opportunity exists for the de-
velopment of fermented functional dairy products with 
the use of specific new LAB. These studies may include 
LAB screening for ACEI, in vivo studies with SHR, and 
clinical trials to test the efficacy of the fermented milk 
product. Before conducting clinical trials, it is extremely 
important to have properly designed randomized, con-
trolled, double-blind studies to avoid methodological 
limitations and an adequate sample size to give enough 
power to detect differences between groups. It is also 
important to develop the regulatory legislation that al-
lows the introduction of health claims for functional 
dairy foods, especially in countries where this subject is 
underdeveloped. Finally, the development of functional 
foods that support a healthy heart through lowering 
blood pressure offers new market opportunities.
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